Inge Jedema

3.2k total citations
79 papers, 1.8k citations indexed

About

Inge Jedema is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, Inge Jedema has authored 79 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Immunology, 29 papers in Hematology and 25 papers in Oncology. Recurrent topics in Inge Jedema's work include Immune Cell Function and Interaction (33 papers), T-cell and B-cell Immunology (31 papers) and Immunotherapy and Immune Responses (26 papers). Inge Jedema is often cited by papers focused on Immune Cell Function and Interaction (33 papers), T-cell and B-cell Immunology (31 papers) and Immunotherapy and Immune Responses (26 papers). Inge Jedema collaborates with scholars based in Netherlands, United States and Germany. Inge Jedema's co-authors include J.H. Frederik Falkenburg, Roel Willemze, Renée M. Y. Barge, Mirjam H.M. Heemskerk, Michel G.D. Kester, Simone A.P. van Luxemburg-Heijs, Marieke Griffioen, Vincent H. J. van der Velden, Nicole M. van der Werff and Jacques J. M. van Dongen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Blood.

In The Last Decade

Inge Jedema

76 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Inge Jedema Netherlands	24	998	776	657	421	254	79	1.8k
Paulo Vidal Campregher Brazil	12	950 1.0×	569 0.7×	429 0.7×	323 0.8×	140 0.6×	57	1.7k
Jochen Greiner Germany	27	1.4k 1.4×	1.1k 1.4×	871 1.3×	984 2.3×	224 0.9×	92	2.7k
Andries C. Bloem Netherlands	23	709 0.7×	628 0.8×	792 1.2×	706 1.7×	126 0.5×	57	1.9k
Cornelis A.M. van Bergen Netherlands	20	949 1.0×	480 0.6×	622 0.9×	232 0.6×	92 0.4×	53	1.3k
Martin Guimond United States	23	1.2k 1.2×	465 0.6×	642 1.0×	593 1.4×	137 0.5×	43	2.0k
Elisabetta Zappone Italy	13	717 0.7×	924 1.2×	572 0.9×	552 1.3×	239 0.9×	28	1.8k
Patrick Schlegel Germany	17	498 0.5×	529 0.7×	329 0.5×	200 0.5×	94 0.4×	44	1.1k
Michelle A. Hurchla United States	16	1.3k 1.3×	784 1.0×	166 0.3×	408 1.0×	259 1.0×	24	2.0k
Ekaterina Doubrovina United States	21	832 0.8×	972 1.3×	168 0.3×	373 0.9×	310 1.2×	59	1.7k
Ludger Große‐Hovest Germany	19	712 0.7×	655 0.8×	221 0.3×	282 0.7×	79 0.3×	46	1.2k

Countries citing papers authored by Inge Jedema

Since Specialization

Citations

This map shows the geographic impact of Inge Jedema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge Jedema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge Jedema more than expected).

Fields of papers citing papers by Inge Jedema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge Jedema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge Jedema. The network helps show where Inge Jedema may publish in the future.

Co-authorship network of co-authors of Inge Jedema

This figure shows the co-authorship network connecting the top 25 collaborators of Inge Jedema. A scholar is included among the top collaborators of Inge Jedema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge Jedema. Inge Jedema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seijkens, Tom, et al.. (2025). Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors. Nature Reviews Nephrology. 21(10). 687–701.

Borch, Troels Holz, Maartje W. Rohaan, Inge Jedema, et al.. (2023). 57P Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL). Immuno-Oncology Technology. 20. 100530–100530. 1 indexed citations

Kester, Michel G.D., Lois Hageman, Arnoud H. de Ru, et al.. (2022). Promiscuity of Peptides Presented in HLA-DP Molecules from Different Immunogenicity Groups Is Associated With T-Cell Cross-Reactivity. Frontiers in Immunology. 13. 831822–831822. 10 indexed citations

Balen, Peter van, Lothar Germeroth, Lois Hageman, et al.. (2019). Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation—a phase I/II study. Leukemia. 34(3). 831–844. 19 indexed citations

Loeff, Floris C., Dirk Jan A. R. Moes, Peter A. von dem Borne, et al.. (2019). Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft. Transplant Immunology. 57. 101209–101209. 8 indexed citations

Hageman, Lois, Ellis van Liempt, Michel G.D. Kester, et al.. (2018). The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology. Cytotherapy. 20(4). 543–555. 9 indexed citations

Marijt, Erik W.A., et al.. (2018). Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution. Biology of Blood and Marrow Transplantation. 24(9). 1776–1782. 23 indexed citations

Heiden, Pim L. J. van der, Marian van de Meent, Liesbeth C. de Wreede, et al.. (2018). CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity. Transplant Immunology. 49. 54–58. 6 indexed citations

Balen, Peter van, Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs, et al.. (2018). CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. Frontiers in Immunology. 9. 3016–3016. 27 indexed citations

10.

Balen, Peter van, Alwine B. Kruisselbrink, Károly Szuhai, et al.. (2018). Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction. Frontiers in Immunology. 9. 331–331. 6 indexed citations

11.

Hagedoorn, Renate S., Michel G.D. Kester, Dirk M. van der Steen, et al.. (2017). Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia. Blood. 130. 168–168. 1 indexed citations

12.

Kothari, Anisha, Floris C. Loeff, Joshua M. Eichhorn, et al.. (2015). BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. Cancer Research. 75(7). 1366–1375. 72 indexed citations

13.

Amir, Avital L., Dirk M. van der Steen, Marleen M. van Loenen, et al.. (2011). PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer. Clinical Cancer Research. 17(17). 5615–5625. 92 indexed citations

14.

Jedema, Inge, et al.. (2011). Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells. Haematologica. 96(8). 1204–1212. 22 indexed citations

15.

Rutten, Caroline E., Simone A.P. van Luxemburg-Heijs, Marieke Griffioen, et al.. (2008). HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia. 22(7). 1387–1394. 44 indexed citations

16.

Bergen, Cornelis A.M. van, Michel G.D. Kester, Inge Jedema, et al.. (2007). Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood. 109(9). 4089–4096. 60 indexed citations

17.

Borne, Peter A. von dem, Simone A.P. van Luxemburg-Heijs, Mirjam H.M. Heemskerk, et al.. (2006). Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia. 20(6). 1040–1046. 13 indexed citations

18.

Vries, Jeltje F. de, Linda J. Wammes, Inge Jedema, et al.. (2006). Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria. APOPTOSIS. 12(1). 181–193. 19 indexed citations

19.

Jedema, Inge, Renée M. Y. Barge, Roel Willemze, & JH Falkenburg. (2003). High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment. Leukemia. 17(3). 576–584. 25 indexed citations

20.

Jedema, Inge, Renée M. Y. Barge, Vincent H. J. van der Velden, et al.. (2003). Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 18(2). 316–325. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact